Application of the Micro Pixel Photon Counter to calorimetry and PET

Technological solutions are being investigated, in both fields of calorimetry and positron emission tomography, to increase the granularity of the detectors and achieve a better imaging resolution. The Geiger-mode avalanche photodiode looks a promising photo-detector for these compact designs. Up to now, the main limit of its application was the detection of the scintillation light, mostly ranging in the blue region: the traditional Geiger-mode avalanche photodiode is green sensitive. Hamamatsu has recently released a photo-detector of the same family, the Micro Pixel Photon Counter (MPPC), with a high photo-detection efficiency in the 420nm spectral region, opening a new scenario for the scintillator-based systems. The direct readout performances of a MPPC directly coupled to a plastic organic scintillator and to an inorganic scintillator (LSO) are systematically studied. Possible applications in highly granular calorimeters and positron emission tomography detectors are discussed

Chronic exertional compartment syndrome of the forearm: a systematic review

The aim of this systematic review is to understand which surgical procedure provides better results in terms of pain relief and function in the treatment of chronic exertional compartment syndrome (CECS) of the forearm. We searched Medline (PubMed), Web of Science, Embase and Scopus databases on 8 July 2020. Twelve studies were included in this review. We assessed the quality of the studies using the Coleman Methodological Score. Data on demographic features, operative readings, diagnostic methods, follow-up periods, type and rates of complications, survivorship of the procedure, return to sport activity, and outcome measures were recorded. In conclusion, compared to the other techniques, endoscopic fasciotomy delivers similar success rates and lower incidence of complications

bullous wells syndrome associated with non hodgkin s lymphocytic lymphoma

3/µl; eosinophils 14.3% neutrophils 48%, lymphocytes 31.2%, monocytes 6.5%, basophils 0.2%), total immunoglobulin E (IgE) = 751 IU/ml, C-reactive protein (CRP) 1.25 mg/dl, erythrocyte sedimentation rate (ESR) in the first hour 60 mm; viral markers (Epstein Barr virus, cytomegalovirus, hepatitis A, B and C virus), cryoglobulin, ANCA, LAC, ANA, ENA and anti-DNA antibodies were all negative. Histopathological examination of the lesion on the left leg showed an epidermis characterized by multiple, sometimes confluent vesicles containing serum and eosinophil granulocytes. The underlying papillary dermis was markedly oedematous, with focal and minimal erythrocytic extravasations and an interstitial eosinophil granulocytic infiltrate. The reticular dermis was infiltrated by a large number of prevalently perivascular lymphocytic elements and numerous perivascular and interstitial eosinophil granulocytes, which also extended along the interlobular hypodermal septa and, to a lesser extent, the hypodermic lobules. The reticular dermis also showed some small and isolated flame figures (Fig. 2). The diagnosis of Wells' syndrome was made on the basis of the clinical picture and the histological findings, together with a negative direct immunofluorescence test (5). Having excluded pharmacological, infective, vasculitic and inflammatory causes, the subsequent instrumental and laboratory investigations were aimed at identifying a possible relapse of the patient's previous neoplastic disease. Complete abdominal ultrasonography, chest radiography and colonoscopy were negative, as was a search for tumour markers. The physical examination findings of numerous swollen inguinal and axillary lymph nodes therefore drew our attention to a possible underlying lymphoproliferative disease, and a subsequent lymph node biopsy revealed a picture compatible with a diffuse, small-cell non-Hodgkin's B lymphoma/ B-cell CLL, which was confirmed by a bone marrow biopsy

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis

Purpose: This meta-analysis summarizes the incidence of treatment-related adverse events (AE) of BRAFi and MEKi. Methods: A systematic search of Medline/PubMed was conducted to identify suitable articles published in English up to 31 December 2021. The primary outcomes were profiles for all-grade and grade 3 or higher treatment-related AEs, and the analysis of single side effects belonging to both categories. Results: The overall incidence of treatment-related all-grade Aes was 99% for Encorafenib (95% CI: 0.97–1.00) and 97% for Trametinib (95% CI: 0.92–0.99; I2 = 66%) and Binimetinib (95% CI: 0.94–0.99; I2 = 0%). In combined therapies, the rate was 98% for both Vemurafenib + Cobimetinib (95% CI: 0.96–0.99; I2 = 77%) and Encorafenib + Binimetinib (95% CI: 0.96–1.00). Grade 3 or higher adverse events were reported in 69% of cases for Binimetinib (95% CI: 0.50–0.84; I2 = 71%), 68% for Encorafenib (95% CI: 0.61–0.74), and 72% for Vemurafenib + Cobimetinib (95% CI: 0.65–0.79; I2 = 84%). The most common grade 1–2 AEs were pyrexia (43%) and fatigue (28%) for Dabrafenib + Trametinib and diarrhea for both Vemurafenib + Cobimetinib (52%) and Encorafenib + Binimetinib (34%). The most common AEs of grade 3 or higher were pyrexia, rash, and hypertension for Dabrafenib + Trametinib (6%), rash and hypertension for Encorafenib + Binimetinib (6%), and increased AST and ALT for Vemurafenib + Cobimetinib (10%). Conclusions: Our study provides comprehensive data on treatment-related adverse events of BRAFi and MEKi combination therapies, showing related toxicity profiles to offer a helpful tool for clinicians in the choice of therapy

Perioperative use of prothrombin complex concentrates

Prothrombin complex concentrates (PCCs) are purified drug products with hemostatic activity derived from a plasma pool. Today, PCCs contain a given and proportional amount of four non-activated vitamin K-dependent coagulation factors (II, VII, IX, and X), a variable amount of anticoagulant proteins (proteins C and S, and in some antithrombin) and low-dose heparin. In some countries PCC products contained only three clotting factors, II, IX, and X. Dosage recommendations are based on IU of F-IX, so that one IU of F-IX represents the activity of F-IX in 1 mL of plasma. Reversion of the anticoagulant effect of vitamin K antagonists (VKAs) in cases of symptomatic overdose, active bleeding episodes, or need for emergency surgery is the most important indication for PCCs and this effect of PCCs appears to be more complete and rapid than that caused by administration of fresh frozen plasma. They may be considered as safe preparations if they are used for their approved indications at the recommended dosage with adequate precautions for administration, and have been shown to be effective for reversing the effect of VKAs. Their adequate use based on decision algorithms in the perioperative setting allows a rapid normalization of International Normalized Ratio (INR) for performing emergency surgery, minimizing bleeding risk. This review aims to propose two algorithms for the use of PCCs in the perioperative setting, one to calculate the PCCs dose to be administered in a bleeding patient and/or immediately before urgent surgery, based on patient's clinical status, prior INR and INR target and another for reversing the action of oral anticoagulants depending on urgency of surgery

Hadron attenuation in deep inelastic lepton-nucleus scattering

We present a detailed theoretical investigation of hadron attenuation in deep inelastic scattering (DIS) off complex nuclei in the kinematic regime of the HERMES experiment. The analysis is carried out in the framework of a probabilistic coupled-channel transport model based on the Boltzmann-Uehling-Uhlenbeck (BUU) equation, which allows for a treatment of the final-state interactions (FSI) beyond simple absorption mechanisms. Furthermore, our event-by-event simulations account for the kinematic cuts of the experiments as well as the geometrical acceptance of the detectors. We calculate the multiplicity ratios of charged hadrons for various nuclear targets relative to deuterium as a function of the photon energy nu, the hadron energy fraction z_h=E_h/nu and the transverse momentum p_T. We also confront our model results on double-hadron attenuation with recent experimental data. Separately, we compare the attenuation of identified hadrons (pi^\pm, \pi^0, K^\pm, p and pbar) on Ne and Kr targets with the data from the HERMES Collaboration and make predictions for a Xe target. At the end we turn towards hadron attenuation on Cu nuclei at EMC energies. Our studies demonstrate that (pre-)hadronic final-state interactions play a dominant role in the kinematic regime of the HERMES experiment while our present approach overestimates the attenuation at EMC energies.Comment: 61 pages, 19 figures, version accepted for publication in Phys. Rev.

Fast and reasonable Installation, Experience and Acceptance of a Remote Control Room

Remote control systems are becoming more and more important to give us the flexibility to control facilities, provide assistance and intervene in case of problems at any time and from every place. As a global operating group CALICE [2] with approx. 220 members worldwide is dependent on using a remote control system for shifts and monitoring of the data taking. CALICE has at present installed its detector at Fermilab, Chicago, where will run test beam experiments for the next year. The components of the remote control system and kind of use are presented here.Comment: 4 page

Qualification of piezo-electric actuators for the MADMAX booster system at cryogenic temperatures and high magnetic fields

We report on the qualification of a piezo-based linear stage for the manipulation of positions of dielectric discs in the booster of the MADMAX axion dark matter search experiment. A first demonstrator of the piezo drives, specifically developed for MADMAX, was tested at room temperature as well as at cryogenic temperatures down to 4.5 K and inside strong magnetic fields up to 5.3 T. These qualification measurements prove that the piezo-based linear stage is suited for MADMAX and fulfills the requirements.Comment: 13 pages, 9 figures, 2 table